MedTrace Logo

A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C

NCT00890318 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2010-10-21

No results posted yet for this study

Summary

The purpose of this study is to determine multiple dose safety, tolerability and pharmacokinetics of ABT-072 under nonfasting conditions in healthy adult subjects, and to determine the effect of single dose administration of ketoconazole on steady state ABT-072 pharmacokinetics.

Conditions

  • HCV Infection

Interventions

DRUG

ABT-072

Powder contents from capsules mixed in an alternative vehicle, for additional information refer to Arm Description.

OTHER

ketoconazole

Tablet, see Arm Description for intervention information.

DRUG

Placebo

Capsule or powder drug substance from the capsule mixed in an alternative vehicle, for additional information refer to Arm Description.

Sponsors & Collaborators

Principal Investigators

  • Daniel Cohen, MD · Abbott

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00890318 on ClinicalTrials.gov